Wegovy HD Cleared in 54 Days: What the FDA's New Voucher Pathway Means for Peptide Drugs

What the data shows

Wegovy HD's approval rests on two 72-week phase 3 trials. STEP UP enrolled roughly 1,400 adults with obesity and produced a mean weight loss of 20.7% on semaglutide 7.2 mg versus about 15% on the existing 2.4 mg dose. Roughly one in three participants on the high dose reached 25% or greater body-weight reduction. STEP UP T2D, in 500 adults with obesity and type 2 diabetes, delivered 14.1% mean weight loss.

So the efficacy case is real: a higher dose produces meaningfully more weight loss in patients who have plateaued on 2.4 mg. The label restricts Wegovy HD to patients who have tolerated 2.4 mg for at least four weeks and still need additional weight reduction.

One safety signal is worth flagging. At the 7.2 mg dose, altered skin sensation — described as sensitivity, pain, burning, or dysesthesia — was reported by 22% of participants, compared to 6% on 2.4 mg and essentially zero on placebo. Most cases resolved on their own or with dose reduction, but the FDA noted it is continuing to investigate. That's a class signal that wasn't visible at lower doses.

The CNPV pathway, briefly

The Commissioner's National Priority Voucher program launched in June 2025 to compress FDA review timelines for products that align with what the agency labels "national priorities." Wegovy HD was the fourth CNPV approval. The 54-day review is roughly an order of magnitude shorter than standard pathways and four times faster than priority review.

This is, on the face of it, good news. Faster reviews mean faster patient access when the data is strong. The agency framing has been emphatic — the FDA Commissioner described the approval as "unprecedented efficiency."

What we'd want to watch

The honest read is that CNPV speed depends entirely on which products get the voucher. A few questions are worth asking as the pathway matures:

How is "national priority" defined? A higher dose of an existing well-characterized molecule with two phase 3 trials is one thing. The criterion becomes more consequential when applied to novel mechanisms or compounds with thinner clinical packages.

Post-marketing surveillance. A 54-day review is fine when safety questions are well-characterized at lower doses. The dysesthesia signal at 7.2 mg is exactly what traditional post-marketing follow-up is designed to characterize — and the FDA has said it is investigating. The question is whether resourcing keeps up.

Industry incentives. If sponsors learn CNPV is achievable for dose-escalation programs more easily than for novel mechanisms, that shapes R&D allocation in ways that may not produce the best long-term peptide pipeline.

Wegovy HD itself is a clear win for patients who need more efficacy than 2.4 mg provides. The pathway it traveled is more interesting than the product.

Related on Grey Peptides